Company Filing History:
2 out of 1,454 
Years Active: 2025
Title: Alessandro Masiero: Innovator in Biopharmaceuticals
Introduction
Alessandro Masiero is a prominent inventor based in Paris, France. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of innovative therapeutic proteins. With a total of 3 patents to his name, Masiero is recognized for his groundbreaking work in enhancing the efficacy of treatments for various diseases.
Latest Patents
Masiero's latest patents include a novel Fc variant with enhanced affinity to Fc receptors and improved thermal stability. This patent provides Fc domain variants, including effector-competent Fc domain variants, along with nucleic acids encoding these variants and host cells for their production. Additionally, he has developed methods for increasing the yield of these Fc domain variants and their application in disease treatment. Another significant patent is for CD28/OX40 bispecific antibodies, which are multispecific binding proteins designed to treat autoimmune diseases. This invention comprises a first antigen binding domain with specificity to CD28 and a second domain with specificity to OX40.
Career Highlights
Alessandro Masiero is currently employed at Sanofi, a leading global biopharmaceutical company. His work at Sanofi has allowed him to focus on innovative solutions that address critical health challenges. His expertise in the field has positioned him as a key player in the development of advanced therapeutic options.
Collaborations
Masiero collaborates with notable colleagues, including Gerald Beste and Yanik Bruynooghe. These partnerships enhance the research and development efforts within the biopharmaceutical sector, fostering innovation and progress.
Conclusion
Alessandro Masiero's contributions to biopharmaceuticals through his patents and collaborations highlight his role as a leading inventor in the industry. His work continues to pave the way for advancements in therapeutic treatments, making a significant impact on healthcare.